Ottawa Heart Institute Adopts Ondine’s Steriwave for Cardiac Surgeries

Ondine Biomedical, Inc. ( (GB:OBI) ) has shared an announcement.

The University of Ottawa Heart Institute, Canada’s largest cardiac center, has adopted Ondine Biomedical’s Steriwave nasal photodisinfection as a standard of care for cardiac surgeries, highlighting its commitment to patient safety and infection prevention. This adoption by a leading cardiac care center, along with other major hospitals, underscores the effectiveness of Steriwave in reducing surgical site infections and positions Ondine Biomedical as a key player in infection control innovation.

The most recent analyst rating on (GB:OBI) stock is a Buy with a £50.00 price target. To see the full list of analyst forecasts on Ondine Biomedical, Inc. stock, see the GB:OBI Stock Forecast page.

More about Ondine Biomedical, Inc.

Ondine Biomedical Inc. is a Canadian life sciences company specializing in light-activated antimicrobial therapies, known as photodisinfection, for preventing and treating infections, including those caused by multidrug-resistant organisms. The company has a range of investigational products based on its proprietary technology and is active in several international markets, with its nasal photodisinfection system, Steriwave, approved in Canada, Europe, and other countries.

Average Trading Volume: 140,012

Technical Sentiment Signal: Strong Sell

Current Market Cap: £37.67M

For detailed information about OBI stock, go to TipRanks’ Stock Analysis page.